Evidence map›Paper›PMID 32693210›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2020

Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20

Noa Granot, Andrew R Rezvani, Barbara S Pender, Barry E Storer, Brenda M Sandmaier, Rainer Storb, David G Maloney

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Noa GranotClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Andrew R RezvaniClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, Stanford University Medical Center, Stanford, California.
Barbara S PenderClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Barry E StorerClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Biostatistics, University of Washington, Seattle, Washington.
Brenda M SandmaierClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington.
Rainer StorbClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington.
David G MaloneyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington. Electronic address: dmaloney@fredhutch.org.
Fred Hutch Cancer Center · USUniversity of Washington · USStanford Medicine · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
VIRUS-MEDIATED MYELOSUPPRESSIONP01CA018029 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Evan Newell · 1985 to 2026
$128.4M
Project 3: Stem Cell Allografts for Lymphoid MalignanciesP01CA078902 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SANDMAIER, BRENDA MARIE · 1999 to 2025
$46.1M
CAREER DEVELOPMENT IN PEDIATRIC AND MEDICAL ONCOLOGYK12CA076930 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DAVIDSON, NANCY ELLEN, MESHINCHI, SOHEIL · 1997 to 2025
$13.1M
NCI NIH HHS K12 CA076930NCI NIH HHS P01 CA018029NCI NIH HHS P01 CA078902NCI NIH HHS P30 CA015704
6 · The paper itself

Abstract

We previously reported a 24% 1-year relapse rate in 93 older or medically unfit patients with CD20

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationB-LymphocytesHumansNeoplasm Recurrence, LocalProspective StudiesReceptors, FcRituximabTransplantation ConditioningTransplantation, HomologousReceptors, FcRituximabAllogeneic hematopoietic cell transplantationFCγRIIIa receptorNon-Hodgkin lymphomaNon myeloablative conditioningRelapseRituximab

Identifiers

PMID32693210
PMCPMC7549403
OpenAlexW3042397537

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.